Emergent Health Appoints Marvin Segel, Son of QVC Founder Joseph Segel as Director and Chief Marketing Officer

KING OF PRUSSIA, PA / ACCESSWIRE / February 15, 2022 / Emergent Health Corp., (OTC PINK:EMGE) announces the appointment of Marvin Segel, son of QVC's founder, Joseph Segel, as a Director and the Chief Marketing Officer.

With over 20 years of direct-to-consumer TV and marketing experience, Mr. Segel will serve in a Senior Executive role at Emergent to lead the analysis and development of current and future Health & Wellness products, marketing, advertising and business development based upon his demonstrated track record of multi-million-dollar contributions for developing and launching top-selling Direct-To-Consumer products.

Since January 2020, Mr. Segel has served as President for The Y Networks, the first network focused on "Content-Based Shopping" allowing the consumer content to engage on-demand across platforms. From August 2015, Mr. Segel served as Chief Operating Officer for Star Shop, LLC., the first celebrity driven social media platform where the intersection of content and commerce come together. From August 2009 through August 2014, Mr. Segel served as Vice President of Business Relationships and Vendor Relations at ShopNBC, n/k/a ShopHQ, an American cable, satellite and broadcasthome shoppingtelevision network and multi-channel video retailer owned by iMedia Brands. At ShopNBC, Mr. Segel conceptualized and developed the first iPhone app for any shopping channel, leveraged a relationship with a top iPhone app provider in order to accelerate development and become the first to launch, introduced the top-selling beauty product, Wrinkle Magic, to ShopNBC, and generated millions in revenue, and launched multiple concepts: Harley Davidson Clothing, Sur La Table, NBA Collectables, Mark Cuban America's Dream, and DITKA Steakhouse Steaks, coordinated GE, BMW, SEARS and YAMAHA Boat product placement on ShopNBC, switching Frigidaire appliances in the ShopNBC kitchen to GE and managed The Vendor Contact Database for Finance and Vendor Relations. From 1999 until 2009, Mr. Segel established Segel Associates to strategically guide consumer products manufacturers to introduce and distribute products through electronic retail channels, primarily QVC and ShopNBC. At Segel Associates, he directed product development, formulation and flavor varieties for the top-selling weight loss product that he personally sold on QVC for 10 years, driving sales to $14 million annually in the US and UK.

Marvin Segel, newly appointed CMO of Emergent, stated, "Giving the Consumer healthier options in this crazy world for themselves and their family pets means a lot to me. The value of the family pet has become even more important to everyone while in quarantine. Segel continued & "Pets give amazing emotional support!"

James Zimbler, CEO of Emergent added "It's a tremendous victory to add the multi-talented, enormously experienced and my good friend Marvin Segel to oversee the creation, marketing and distribution of Emergent's line of Health and Wellness products. Marvin's vast network developed over the past 30 years, mastering Direct-to-Consumer and Online TV Shopping sales, positions Emergent for maximum market penetration and ultimate success."

ABOUT EMERGENT HEALTH CORPORATION

Emergent Health Corp.develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, online and various other retail outlets throughout the United States and internationally. PharmaZu Corp., its newly acquired subsidiary is a pure play, e-commerce products and service provider focused on the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR MORE INFORMATION, PLEASE CONTACT:

James Zimbler, CEO
[email protected]
631-806-1420

SOURCE: Emergent Health Corp.

View source version on accesswire.com:
https://www.accesswire.com/688736/Emergent-Health-Appoints-Marvin-Segel-Son-of-QVC-Founder-Joseph-Segel-as-Director-and-Chief-Marketing-Officer

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CTT Systems AB (publ.) - Interim Report First Quarter 2024
• iZafe Group's Quarterly Report January-March 2024
• JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension